Soleus Capital Management
Latest statistics and disclosures from Soleus Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, UTHR, EDAP, IOVA, TEVA, and represent 31.37% of Soleus Capital Management's stock portfolio.
- Added to shares of these 10 stocks: XBI (+$209M), IOVA (+$44M), TGTX (+$38M), JSPR (+$35M), BGNE (+$23M), KROS (+$18M), BIIB (+$16M), CSTL (+$16M), RVMD (+$15M), NRIX (+$14M).
- Started 32 new stock positions in RGLS, OLMA, MNKD, BIIB, DNTH, ENGN, NKTX, ORIC, KROS, BGNE.
- Reduced shares in these 10 stocks: Rayzebio (-$46M), GSK (-$41M), VKTX (-$30M), TEVA (-$29M), MREO (-$24M), HCA (-$17M), NUVL (-$15M), PCVX (-$14M), , .
- Sold out of its positions in ABBV, Adverum Biotechnologies, ATRC, CVS, Harpoon Therapeutics, HOLX, ILMN, ImmunoGen, Jasper Therapeutics, Rayzebio. SIBN, SNN, VYNE, XENE.
- Soleus Capital Management was a net buyer of stock by $313M.
- Soleus Capital Management has $1.3B in assets under management (AUM), dropping by 49.51%.
- Central Index Key (CIK): 0001802630
Tip: Access up to 7 years of quarterly data
Positions held by Soleus Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Soleus Capital Management
Soleus Capital Management holds 91 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 15.5 | $209M | NEW | 2.2M | 94.89 |
|
| United Therapeutics Corporation (UTHR) | 4.4 | $60M | +4% | 260k | 229.72 |
|
| Edap Tms S A Sponsored Adr (EDAP) | 3.9 | $53M | 7.2M | 7.35 |
|
|
| Iovance Biotherapeutics (IOVA) | 3.9 | $52M | +531% | 3.5M | 14.82 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 3.7 | $49M | -37% | 3.5M | 14.11 |
|
| Tg Therapeutics (TGTX) | 3.6 | $48M | +387% | 3.2M | 15.21 |
|
| Celcuity (CELC) | 2.8 | $37M | -20% | 1.7M | 21.60 |
|
| Jasper Therapeutics Com New (JSPR) | 2.6 | $35M | NEW | 1.2M | 29.36 |
|
| Neuropace (NPCE) | 2.4 | $32M | 2.4M | 13.20 |
|
|
| Essa Pharma Com New (EPIX) | 2.3 | $31M | -17% | 3.6M | 8.49 |
|
| Organogenesis Hldgs (ORGO) | 2.0 | $27M | +6% | 9.6M | 2.84 |
|
| Axogen (AXGN) | 1.9 | $25M | +19% | 3.1M | 8.07 |
|
| Humana (HUM) | 1.9 | $25M | -2% | 72k | 346.72 |
|
| SurModics (SRDX) | 1.7 | $24M | +3% | 801k | 29.34 |
|
| Revolution Medicines (RVMD) | 1.7 | $24M | +189% | 729k | 32.23 |
|
| Ideaya Biosciences (IDYA) | 1.7 | $23M | -5% | 534k | 43.88 |
|
| Beigene Sponsored Adr (BGNE) | 1.7 | $23M | NEW | 148k | 156.39 |
|
| C4 Therapeutics Com Stk (CCCC) | 1.5 | $20M | +33% | 2.5M | 8.17 |
|
| Penumbra (PEN) | 1.4 | $19M | +7% | 86k | 223.18 |
|
| Verastem Com New (VSTM) | 1.3 | $18M | +8% | 1.5M | 11.80 |
|
| Keros Therapeutics (KROS) | 1.3 | $18M | NEW | 274k | 66.20 |
|
| Treace Med Concepts (TMCI) | 1.3 | $18M | +32% | 1.3M | 13.05 |
|
| Hca Holdings (HCA) | 1.3 | $17M | -49% | 51k | 333.53 |
|
| Nurix Therapeutics (NRIX) | 1.2 | $16M | +679% | 1.1M | 14.70 |
|
| Castle Biosciences (CSTL) | 1.2 | $16M | +2690% | 726k | 22.15 |
|
| Iradimed (IRMD) | 1.2 | $16M | -43% | 362k | 43.99 |
|
| Biogen Idec (BIIB) | 1.2 | $16M | NEW | 73k | 215.63 |
|
| Krystal Biotech (KRYS) | 1.1 | $15M | +110% | 84k | 177.93 |
|
| Vaxcyte (PCVX) | 1.1 | $14M | -49% | 208k | 68.31 |
|
| Bioatla (BCAB) | 1.0 | $14M | 4.1M | 3.44 |
|
|
| GSK Sponsored Adr (GSK) | 1.0 | $14M | -75% | 319k | 42.87 |
|
| Rigel Pharmaceuticals Com New (RIGL) | 1.0 | $14M | -2% | 9.2M | 1.48 |
|
| Engene Holdings (ENGN) | 1.0 | $14M | NEW | 800k | 16.95 |
|
| Inari Medical Ord (NARI) | 1.0 | $13M | NEW | 277k | 47.98 |
|
| Novocure Ord Shs (NVCR) | 0.8 | $11M | +131% | 696k | 15.63 |
|
| Tango Therapeutics (TNGX) | 0.8 | $11M | +59% | 1.4M | 7.94 |
|
| Applied Therapeutics (APLT) | 0.8 | $11M | +239% | 1.6M | 6.80 |
|
| Arcellx Common Stock (ACLX) | 0.8 | $10M | -5% | 150k | 69.55 |
|
| Enanta Pharmaceuticals (ENTA) | 0.8 | $10M | NEW | 581k | 17.46 |
|
| Nuvalent Inc-a (NUVL) | 0.7 | $9.7M | -59% | 129k | 75.09 |
|
| Immunic (IMUX) | 0.7 | $9.6M | +2331% | 7.3M | 1.32 |
|
| Cg Oncology | 0.7 | $9.6M | NEW | 218k | 43.90 |
|
| Inhibrx (INBX) | 0.7 | $9.4M | +1685% | 268k | 34.96 |
|
| Pharvaris N V (PHVS) | 0.7 | $9.3M | +84% | 402k | 23.11 |
|
| Y Mabs Therapeutics (YMAB) | 0.7 | $9.3M | +263% | 571k | 16.26 |
|
| Merus N V (MRUS) | 0.7 | $8.8M | -35% | 196k | 45.03 |
|
| Syndax Pharmaceuticals (SNDX) | 0.7 | $8.8M | -28% | 369k | 23.80 |
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.6 | $8.6M | -73% | 2.6M | 3.30 |
|
| Immunovant (IMVT) | 0.6 | $8.6M | -16% | 265k | 32.31 |
|
| Theratechnologies Com New (THTX) | 0.6 | $8.0M | 4.8M | 1.66 |
|
|
| Natera (NTRA) | 0.6 | $8.0M | NEW | 87k | 91.46 |
|
| Olema Pharmaceuticals (OLMA) | 0.6 | $7.4M | NEW | 658k | 11.32 |
|
| Genedx Holdings Corp Com Cl A (WGS) | 0.5 | $7.2M | +1205% | 783k | 9.13 |
|
| Bausch Health Companies (BHC) | 0.5 | $7.1M | NEW | 670k | 10.61 |
|
| Mannkind Corp Com New (MNKD) | 0.5 | $7.1M | NEW | 1.6M | 4.53 |
|
| Mind Medicine Mindmed Com New (MNMD) | 0.5 | $7.1M | NEW | 750k | 9.40 |
|
| Insmed Com Par $.01 (INSM) | 0.5 | $6.8M | +49% | 250k | 27.13 |
|
| Fate Therapeutics (FATE) | 0.5 | $6.4M | NEW | 870k | 7.34 |
|
| X4 Pharmaceuticals (XFOR) | 0.5 | $6.4M | NEW | 4.6M | 1.39 |
|
| 4d Molecular Therapeutics In (FDMT) | 0.5 | $6.3M | +330% | 197k | 31.86 |
|
| Miragen Therapeutics (VRDN) | 0.4 | $6.0M | +146% | 340k | 17.51 |
|
| Janux Therapeutics (JANX) | 0.4 | $5.9M | NEW | 158k | 37.65 |
|
| Oric Pharmaceuticals (ORIC) | 0.4 | $5.8M | NEW | 421k | 13.75 |
|
| Viking Therapeutics (VKTX) | 0.4 | $5.5M | -84% | 67k | 82.00 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.3 | $4.7M | -41% | 566k | 8.32 |
|
| Kalvista Pharmaceuticals (KALV) | 0.3 | $4.6M | NEW | 386k | 11.86 |
|
| Regulus Therapeutics (RGLS) | 0.3 | $4.5M | NEW | 1.6M | 2.88 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.3 | $3.8M | +61% | 153k | 24.90 |
|
| Inspiremd (NSPR) | 0.2 | $3.3M | 1.4M | 2.37 |
|
|
| Calcimedica Com New (CALC) | 0.2 | $3.3M | NEW | 784k | 4.16 |
|
| Nkarta (NKTX) | 0.2 | $3.2M | NEW | 300k | 10.81 |
|
| Dianthus Therapeutics (DNTH) | 0.2 | $3.0M | NEW | 100k | 30.00 |
|
| Cervomed (CRVO) | 0.2 | $3.0M | NEW | 127k | 23.30 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.2 | $2.7M | NEW | 925k | 2.87 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.2 | $2.3M | NEW | 37k | 61.02 |
|
| Evolus (EOLS) | 0.2 | $2.2M | NEW | 160k | 14.00 |
|
| Arcutis Biotherapeutics (ARQT) | 0.2 | $2.2M | NEW | 225k | 9.91 |
|
| Annexon (ANNX) | 0.2 | $2.1M | -43% | 292k | 7.17 |
|
| Apogee Therapeutics (APGE) | 0.1 | $1.3M | -42% | 20k | 66.45 |
|
| Transmedics Group (TMDX) | 0.1 | $1.2M | -86% | 17k | 73.94 |
|
| Avita Therapeutics (RCEL) | 0.1 | $1.2M | 75k | 16.03 |
|
|
| Protagonist Therapeutics (PTGX) | 0.1 | $998k | -58% | 35k | 28.93 |
|
| Denali Therapeutics (DNLI) | 0.1 | $964k | -63% | 47k | 20.52 |
|
| CVRX (CVRX) | 0.1 | $883k | NEW | 49k | 18.21 |
|
| The Beauty Health Company Com Cl A (SKIN) | 0.1 | $755k | +9% | 170k | 4.44 |
|
| Amicus Therapeutics (FOLD) | 0.1 | $683k | NEW | 58k | 11.78 |
|
| Tenaya Therapeutics (TNYA) | 0.0 | $639k | NEW | 122k | 5.23 |
|
| Silk Road Medical Inc Common (SILK) | 0.0 | $183k | -98% | 10k | 18.32 |
|
| Urogen Pharma (URGN) | 0.0 | $150k | NEW | 10k | 15.00 |
|
| Liquidia Corporation Com New (LQDA) | 0.0 | $148k | 10k | 14.75 |
|
|
| Xeris Pharmaceuticals (XERS) | 0.0 | $137k | 62k | 2.21 |
|
Past Filings by Soleus Capital Management
SEC 13F filings are viewable for Soleus Capital Management going back to 2019
- Soleus Capital Management 2024 Q1 filed May 15, 2024
- Soleus Capital Management 2023 Q4 filed Feb. 14, 2024
- Soleus Capital Management 2023 Q3 filed Nov. 14, 2023
- Soleus Capital Management 2023 Q2 filed Aug. 14, 2023
- Soleus Capital Management 2023 Q1 filed May 15, 2023
- Soleus Capital Management 2022 Q4 filed Feb. 14, 2023
- Soleus Capital Management 2022 Q3 filed Nov. 14, 2022
- Soleus Capital Management 2022 Q2 filed Aug. 15, 2022
- Soleus Capital Management 2022 Q1 filed May 16, 2022
- Soleus Capital Management 2021 Q4 filed Feb. 14, 2022
- Soleus Capital Management 2021 Q3 filed Nov. 15, 2021
- Soleus Capital Management 2021 Q2 filed Aug. 16, 2021
- Soleus Capital Management 2021 Q1 filed May 17, 2021
- Soleus Capital Management 2020 Q4 restated filed April 29, 2021
- Soleus Capital Management 2020 Q4 filed Feb. 16, 2021
- Soleus Capital Management 2020 Q3 filed Nov. 13, 2020